Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab-E104 ISAC
- Development stage
- Preclinical
- Lead developer
- Binghamton University
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Sacituzumab-E104 ISAC is a novel immune-stimulating antibody conjugate (ISAC) designed for the treatment of Trop2-expressing cancers, specifically pancreatic cancer. It consists of the anti-Trop2 monoclonal antibody sacituzumab conjugated to E104, a potent Toll-like receptor 7 (TLR7) agonist, via specialized linkers. Developed by researchers at Binghamton University, the conjugate aims to deliver the TLR7 agonist directly to the tumor microenvironment, thereby activating innate immune pathways (NFκB and IRF-7) and inducing pro-inflammatory cytokines like IL-6 while minimizing systemic toxicity. Preclinical evaluations have shown that the ISAC exhibits improved pharmacokinetic properties and reduced aggregation compared to earlier iterations, achieving complete tumor regression in mouse xenograft models of pancreatic cancer.
- Other names
- Trop2-targeting ISACTrop-2-targeting ISACTrop 2-targeting ISACsacituzumab-E104sacituzumab-E-104sacituzumab-E 104
02
Targets
C1Q (Complement C1q)TACSTD2 (Tumor-associated calcium signal transducer 2)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on sacituzumab-E104 ISAC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab-E104 ISAC.